Experiments
Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).
-
Full-text index only
The process chain for peptidomic biomarker discovery.
PMID 16410650 · PMC3850862 · Disease markers · 2006 · 8 claims · 3 setups
Peptidomics (comprehensive analysis of peptides and small proteins <20 kDa) fills a methodological gap left by standard proteomics, which mainly addresses proteins in the ~10-200 kDa range.
-
Full-text index only
Preclinical and post-treatment changes in the HCC-associated serum proteome.
PMID 17060939 · PMC2360589 · British journal of cancer · 2006 · 7 claims · 6 setups
SELDI proteomic profiling of serum reveals consistent, statistically significant changes associated with the development of HCC in hepatitis C patients
-
Full-text index only
Identification of diagnostic markers for tuberculosis by proteomic fingerprinting of serum.
PMID 16980117 · PMC7159276 · Lancet (London, England) · 2006 · 8 claims · 5 setups
An SVM classifier trained on serum proteomic profiles discriminated patients with active tuberculosis from controls with clinically overlapping conditions
-
Full-text index only
Pre-operative urinary cathepsin D is associated with survival in patients with renal cell carcinoma.
PMID 19789534 · PMC2768081 · British journal of cancer · 2009 · 8 claims · 7 setups
Cathepsin D, identified via comparative 2D PAGE of conditioned media from RCC cell lines vs normal renal cultures, is a candidate secreted biomarker of RCC
-
Full-text index only
Sample preparation for serum/plasma profiling and biomarker identification by mass spectrometry.
PMID 17166507 · PMC7094463 · Journal of chromatography. A · 2007 · 8 claims · 8 setups
Standardizing sample preparation procedures for serum/plasma profiling is critical for obtaining reliable biomarkers, since slight procedural changes can produce very different protein profiles.
-
Full-text index only
Mesotrypsin promotes malignant growth of breast cancer cells through shedding of CD109.
PMID 20035377 · PMC2929293 · Breast cancer research and treatment · 2010 · 8 claims · 8 setups
Serine protease inhibitors (aprotinin, SBTI) cause morphological reversion of malignant T4-2 breast cancer cells in 3D culture, restoring acinar structure and basal polarity